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Introduction {#sec1}
============

A number of epidemiological studies showed that disturbances of the circadian rhythm strongly correlate with carcinogenesis and tumor progression in humans (for review see [@bib17], [@bib14], [@bib56], [@bib54]). Accordingly, the International Agency for Research on Cancer classified shift work as a group 2A carcinogenic factor ([@bib63]).

The circadian rhythm in mammals is maintained by an integrated network of the central (neural or brain) and peripheral (tissue-specific) clocks. The central clock is located in the suprachiasmatic nucleus of the brain, receives light cues to keep in phase with the light-dark cycle, and synchronizes the peripheral clocks in various tissues through a variety of electrical, endocrine, and metabolic signaling pathways ([@bib2], [@bib55]). At the genetic level, both the central and the peripheral clocks are regulated by an interplay of positive and negative feedback loops involving the same set of clock genes ([@bib73]). Thereby, the bHLH-PAS transcription factors CLOCK (circadian locomotor output cycles kaput) and BMAL1 (brain-muscle Arnt-like protein 1) represent the major components of the core clock\'s positive limb. They induce, among others, the expression of the proteins PER (period 1,2) and CRY (cryptochrome 1,2), which constitute the major arm of the negative limb. The induced PER and CRY proteins then form a complex with each other as well as with modulator proteins such as CK1ε, CKII, or FBXL3 and act as repressors of CLOCK/BMAL heterodimers. Subsequently, they inhibit their own expression as well as those of other CLOCK/BMAL-regulated output genes ([@bib18], [@bib38], [@bib76], [@bib57]). The core loop is interconnected to several other feedback loops, including those of REV-ERBs or PPARα/RORs, which repress or activate BMAL1 expression, respectively ([@bib2], [@bib35], [@bib3]). Overall, the continuous interplay between the core CLOCK/BMAL1 positive limb and the PER/CRY negative limb in concert with post-translational modifications and interconnected loops results in the oscillation of gene expression in a circadian manner.

Several recent studies have linked clock function with the cell cycle and reported that clock components, such as PER1, PER2, BMAL1, and CRY1/2 decrease cell proliferation or improve the action of anti-cancer drugs in different cancer cell lines. Moreover, certain types of human cancer show an altered expression of circadian clock genes (reviewed in [@bib61]).

In addition to disturbances of the circadian clock, most, if not all, solid tumors display hypoxic areas. Hypoxia has been shown to be the major driver of tumor angiogenesis and a critical determinant for proliferation, cell growth, and apoptosis ([@bib60], [@bib43], [@bib27]). Mechanistically, a group of the bHLH-PAS family transcription factors called hypoxia-inducible transcription factors, among which hypoxia-inducible factor (HIF)-1α is the best characterized, mediate the transcriptional adaptation to hypoxia. Thereby, HIF-1α together with its binding partner HIF-1β (also known as aryl hydrocarbon receptor nuclear translocator, ARNT) binds to hypoxia-response elements (HREs) within the promoters of numerous hypoxia-responsive genes ([@bib60], [@bib43], [@bib27]).

The disruption of the circadian rhythm in patients with cancer and the appearance of hypoxia in tumors raises the question whether and how the deregulation of the circadian clock system has an impact on the hypoxia response. Several findings suggested a cross talk between the circadian clock and the hypoxia signaling pathway ([@bib22], [@bib9], [@bib13]), but the mechanisms behind are not completely understood and have just started to emerge. Recent reports have shown that the modulation of oxygen levels can reset the circadian clock at the positive limb in a HIF-1α-dependent manner ([@bib1]) and that HIF-1α and BMAL1 engage in a synergistic cross talk ([@bib71]), which adapts anaerobic metabolism in skeletal muscle ([@bib53]). Although these findings favor the view that this cross talk is bidirectional and would eventually also involve the negative arm of the circadian key players, their participation, in particular that of CRY proteins, remains unknown. In the current study we broaden this view by showing that CRY1, but not CRY2, acts as a repressor of HIFs. This occurs via a specific protein-protein interaction that reduces the binding of HIFs at the HREs of target gene promoters and by altering HIF half-life. Disruption of the CRY1-HIF cross talk at the cellular level shows that CRY1 and HIF-1α have an opposite action on cell growth.

Overall, our study identifies a new level of control that links defects in the circadian clock system with hypoxia signaling and carcinogenesis.

Results {#sec2}
=======

Hypoxia Affects the Circadian Rhythm *In Vivo* {#sec2.1}
----------------------------------------------

To study the possible interplay between the circadian clock and hypoxia we measured the circadian behavior of mice under normoxia (21% O~2~) and hypoxia (17% O~2~) at 12 h + 12 h light/dark (LD) cycles and at constant darkness (dark/dark; DD). When mice were kept under both normoxia and hypoxia at LD they showed circadian periodicity ([Figures 1](#fig1){ref-type="fig"}A and 1B). Intriguingly, we observed that mice at DD lost their circadian rhythm ([Figures 1](#fig1){ref-type="fig"}A and 1B) and expressed HIF target genes when exposed to hypoxia ([Figure 1](#fig1){ref-type="fig"}C). Together, these data indicate that hypoxia is able to modulate the circadian rhythm.Figure 1Representative Actograms of Individually Monitored Mice under Normoxia and Hypoxia at Light-Dark Cycles (LD) and Constant Darkness (DD)(A) Mice were kept under normoxia (n = 14) and hypoxia (B) (n = 14) at 12-h light/12-h dark cycles (LD) for a week, which was followed by another week under the same conditions at constant darkness (DD).(C) Hypoxia-dependent induction of *Cited2* and *Glut-1* mRNA in liver and kidney of the mice after the DD period. The respective mRNA levels were assessed by qRT-PCR, and the values indicate fold-change hypoxia versus normoxia. Boxes represent the interquartile range. Whiskers represent the minimum and maximum observations. \*Significant difference normoxia versus hypoxia.

The Cell-Autonomous Circadian Oscillation in NIH3T3 Cells Is Affected by HIF-1α or HIF-2α {#sec2.2}
-----------------------------------------------------------------------------------------

As the hypoxia-mediated loss of the circadian rhythm in mice at DD stems from systemic and cell-autonomous oscillator effects, we next tested to what extent hypoxia affects the cell-autonomous clock. To do this, we first verified the effect of chronic hypoxia (3% O~2~ for 32 h) in synchronized Per2:Luc-transfected fibroblasts, which possess a cell-autonomous and self-sustained circadian clock ([@bib73], [@bib4]). We found that hypoxia affected the circadian rhythm in two ways, first by reducing the amplitude and second by shortening the period by about 30 min ([Figures 2](#fig2){ref-type="fig"}A and 2B). Given that the response to hypoxia is mainly mediated by an increased abundance of the transcription factors HIF-1α and HIF-2α, we next investigated how HIF-1α or HIF-2α affect the circadian clock. To do this, we first cotransfected an expression vector for a hypoxia-mimicking hydroxylation-resistant HIF-1α variant (P/P/N) ([@bib15]) with the circadian rhythm reporter Bmal1:Luc and analyzed circadian rhythmicity. Similar to hypoxia, overexpression of HIF-1α shortened the circadian period and reduced the amplitude ([Figures 2](#fig2){ref-type="fig"}C and 2D). Overexpression of HIF-2α showed a similar response ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). In contrast to hypoxia and HIFs, the non-specific prolyl hydroxylase inhibitor dimethyloxalylglycine (DMOG), which is often considered as a hypoxia mimetic, lengthened the period ([Figures S1](#mmc1){ref-type="supplementary-material"}C and S1D). Together, these data indicate that HIF-1α and HIF-2α mimic the effect of hypoxia on the circadian clock, whereas the DMOG effects appear to be HIF independent.Figure 2The Circadian Oscillation in NIH3T3 Cells Is Affected by HIF-1α(A and B) (A) Representative examples of the bioluminescence oscillations in NIH3T3^mPer2:Luc^ cells precultured under hypoxia (3% O~2~) for 32 h. (B) Graphical illustration of the amplitude (y axis) and period length (x axis) upon hypoxia treatment. Data are mean ± SEM. \*p \< 0.05.(C) Representative example of the bioluminescence oscillations in NIH3T3 cells cotransfected with an mBmal1:luciferase reporter construct and either empty vector (black line) or HIF-1α P/P/N (green line).(D) Graphical illustration of the amplitude (y axis) and period length (x axis) upon overexpression of HIF-1α P/P/N. Data are mean ± SEM. \*p \< 0.05, \*\*\*p \< 0.001.

The Circadian Oscillation of PAI-1 Is Affected by Hypoxia {#sec2.3}
---------------------------------------------------------

The aforementioned observations appear to be important for genes that are responsive to both hypoxia and the circadian clock. The *SERPINE1* gene encoding plasminogen activator inhibitor-1 (PAI-1) fulfills these criteria and is well known to be a bona fide hypoxia-responsive and circadian-rhythm-regulated gene ([@bib12], [@bib34], [@bib42], [@bib59], [@bib69], [@bib50], [@bib8]). Therefore we investigated whether the hypoxia-induced shifts in circadian rhythmicity are transferred to the expression of hypoxia-responsive target genes and to what extent one or the other response prevails. To examine this, we analyzed PAI-1 expression on protein and reporter gene level in synchronized cells. We found that hypoxia enhanced PAI-1 expression and shortened the circadian period of PAI-1 by about 40 min ([Figures 3](#fig3){ref-type="fig"}A--3D). Together, these data further substantiate that hypoxia and HIFs can advance the period of clock-dependent genes, whereas the amplitude is likely also modulated depending on the transcriptional context.Figure 3The Circadian Oscillation of PAI-1 Expression Is Affected by Hypoxia(A) Representative example of the bioluminescence oscillations in cells stably transfected with a PAI-1 promoter-driven luciferase construct under normoxia and hypoxia.(B and C) (B) Graphical illustration of the amplitude (y axis) and period length (x axis) of PAI-1 promoter-driven luciferase expression under normoxia and hypoxia. Data are mean ± SEM. \*p \< 0.05. (C) Representative western blot analysis of total cell lysates of synchronized Rat-1 fibroblasts probed with PAI-1 and β-actin antibodies.(D) Densitometric analysis of the PAI-1 protein levels presented on (C).

CRY1 Interacts with HIF-1α and HIF-2α {#sec2.4}
-------------------------------------

Accumulating genetic data indicate that the negative limb of the circadian regulators, in particular CRY1, is responsible for maintaining the period length or amplitude of the circadian clock and that CRY1 is the most potent repressor in the clock\'s negative limb ([@bib18], [@bib38], [@bib67], [@bib68], [@bib40], [@bib41], [@bib32], [@bib44], [@bib37], [@bib39], [@bib75], [@bib47]). Based on CRY1\'s potency and responsibility for period and amplitude maintenance and the recent reports on the HIF-1α-BMAL1 cross talk ([@bib71], [@bib53]) as well as the aforementioned findings that HIFs shortened the period and affected the amplitude of the circadian clock, we hypothesized that HIFs would interact with CRY1.

To examine this, we performed coimmunoprecipitation analyses with hypoxic mouse embryonic fibroblasts (MEFs). The assays revealed that CRY1 could be detected when HIF-1α was precipitated from the cells ([Figure 4](#fig4){ref-type="fig"}A). Furthermore, CRY1 could also be detected upon precipitation with HIF-2α antibodies, although the binding signal was low because of the low abundance of HIF-2α ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Next, we verified these interactions and performed western blot analyses from immunoprecipitates of HEK293 cells expressing Myc-tagged HIF-1α, V5-tagged HIF-2α, and hemagglutinin (HA)-tagged CRY1. The blots from anti-Myc-tagged HIF-1α or anti-V5-tagged HIF-2α immunoprecipitations showed the presence of HA-tagged CRY1 when probed with the HA-tag antibody indicating interaction of HIFα proteins and CRY1 ([Figures 4](#fig4){ref-type="fig"}B and [S2](#mmc1){ref-type="supplementary-material"}B). In addition, HIFα proteins were also able to interact with CRY2 ([Figures 4](#fig4){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}C). We also employed a bimolecular fluorescence complementation (BiFC) assay to verify whether these interactions are direct. The BiFC assay takes advantage from the possibility that a fluorescent protein complex can be formed through association of two per se non-interacting and non-fluorescent N-terminal (YN) and C-terminal (YC) fragments of the yellow fluorescent protein (YFP). The complementation of the fluorescent complex is achieved when YN and YC are brought into proximity owing to a direct interaction of the proteins fused to the YN and YC fragments ([Figure 4](#fig4){ref-type="fig"}D) ([@bib31]). We generated vectors allowing expression of fusion proteins consisting of HIF-1α or HIF-2α and the C-terminal part of the YFP (HIF-1α-YC or HIF-2α -YC) as well as of CRY1 and the N-terminal part of the YFP (CRY1-YN). In addition, constructs for the HIFα partner ARNT as well as for the CRY1 partner PER1 served as positive controls to indicate HIF-1α -ARNT or CRY1-PER1 interaction, respectively. The BiFC analyses revealed a strong fluorescent signal when either HIF-1α-YC ([Figures 4](#fig4){ref-type="fig"}E and 4F) or HIF-2α-YC ([Figure S2](#mmc1){ref-type="supplementary-material"}D) and CRY1-YN constructs were applied in the assay. In addition, a clear fluorescent signal could be observed when HIF-1α-YC was coexpressed with ARNT-YN or PER1-YC with CRY1-YN as positive controls ([Figures 4](#fig4){ref-type="fig"}E, [S2](#mmc1){ref-type="supplementary-material"}D, and S2E). By contrast, when HIF-1α-YC or HIF-2α -YC was coexpressed with a vector encoding only YN ([Figures 4](#fig4){ref-type="fig"}E and 4F) no fluorescence was detected. Likewise, the coexpression of YC and YN did not result in the generation of fluorescence, indicating that the separated non-fluorescent fragments did not spontaneously self-assemble ([Figures 4](#fig4){ref-type="fig"}E and 4F). Together, these results indicate that HIF-1α and HIF-2α can interact with CRY1 in living cells.Figure 4CRY1 Interacts with HIF-1α(A) Coimmunoprecipitation (IP) assays from wild-type MEFs cultured under hypoxia in the presence of MG-132. Blots from anti-HIF-1α IPs were probed with the CRY1 and HIF-1α antibody. The blots shown are representative of three independent experiments. IB, immunoblotting.(B and C) Coimmunoprecipitation studies with HEK293 cells, expressing myc-tagged HIF-1α with either (B) HA-tagged CRY1 or (C) V5-tagged CRY2. Blots from anti-myc-tag IPs were probed with HA-tag or V5-tag antibody. The blots shown are representative of three independent experiments.(D and E) BiFC analysis. (D) Schematic representation of expressed proteins employed in BiFC. The sequences encoding amino acid residues 1--154 (N-terminus \[YN\]) or 155--238 (C-terminus \[YC\]) of the yellow fluorescent protein (YFP) were fused to the 3′ ends of the coding regions for HIF-1α, CRY1, or ARNT to generate HIF-1α -YC, CRY1-YN, and ARNT-YN, respectively. YN and YC are non-fluorescent fragments that do not interact per se with each other. An interaction between the proteins fused to the YN and YC fragments facilitates their association to form a bimolecular fluorescent complex. (E) Visualization of the BiFC signal by confocal microscopy. COS-7 cells cotransfected with the expression vectors for HIF-1α-YC, CRY1-YN, ARNT-YN, and vectors encoding only YN or YC were cultured on glass slides for 24 h. The fluorescence detection was performed using specific filter sets for YFP and DAPI. Scale bar, 10 μm.(F) Quantification of the BiFC signal. Cells were transfected as in (E) and quantified by flow cytometry (cf. [Transparent Methods](#mmc1){ref-type="supplementary-material"}). The cytomegalovirus promoter (CMV) driven-YFP signal was set to 100%. Data are mean ± SEM. \*p \< 0.05.

The Tail Region of CRY-1 Interacts with HIF-1α {#sec2.5}
----------------------------------------------

To find out which domain within CRY1 interacts with HIF-1α, we expressed Myc-tagged HIF1α along with different HA-tagged CRY1 protein variants in HEK293 cells ([Figure 5](#fig5){ref-type="fig"}A) and analyzed their interaction by coimmunoprecipitation experiments. Full-length CRY1 interacted with HIF-1α, but this interaction was lost when CRY1 proteins lacking either the CC and tail region or only the tail region were employed in the assays ([Figure 5](#fig5){ref-type="fig"}B). Thus, these data indicate that the tail region of CRY1 is necessary for the interaction of CRY1 with HIF-1α.Figure 5The Tail Domain of CRY1 Is Responsible for Interaction with HIF-1α(A) Schematic representation of the HA-tagged CRY1 protein variants.(B) HEK293 cells were transfected with myc-tagged HIF-1α together with HA-tagged full-length CRY1 or its mutants, cell extracts were prepared and immunoprecipitated with an anti-myc-tag antibody, and precipitates were analyzed by immunoblot with an anti-HA-tag antibody. As a control the expression levels of the CRY1 protein variants as well as myc-tagged HIF-1α were verified in whole-cell extracts (Input). IP, immunoprecipitation; IB, immunoblotting.

CRY1 Interacts with the bHLH Domain of HIF-1α {#sec2.6}
---------------------------------------------

To map the exact HIF-1α domain that interacts with CRY1, we designed several Myc-tagged HIF-1α deletion mutants comprising one or several domains ([Figure 6](#fig6){ref-type="fig"}A) and performed coimmunoprecipitation experiments in HA-CRY1 expressing HEK293 cells. When full-length HIF-1α or its deletion variants were pulled down with anti-Myc-tag antibodies we found that HA-CRY1 coprecipitated full-length HIF-1α and all deletion variants except the HIF-1α mutant lacking the bHLH domain ([Figure 6](#fig6){ref-type="fig"}B). Together, these results indicate that CRY1 interacts with the bHLH domain of HIF-1α.Figure 6The bHLH Domain of HIF-1α Is Responsible for Interaction with CRY1(A) Schematic representation of the myc-tagged HIF-1α protein variants.(B) Coimmunoprecipitation experiments were performed with total proteins from HEK293 cells expressing HA-tagged CRY1 and myc-tagged full-length HIF-1α or its deletion variants. Anti-myc-tag antibody (IP, immunoprecipitation)-precipitated proteins were analyzed by immunoblot (IB, immunoblotting) using an anti-HA-tag antibody. As a control the expression levels of HIF-1α, its deletion variants, as well as the HA-tagged CRY1 proteins were verified in whole-cell extracts (Input).

CRY1 Inhibits Binding of HIF-1α to Its Target Gene Promoters {#sec2.7}
------------------------------------------------------------

As CRY1 interacts with the HIF-1α bHLH domain, which primarily facilitates binding to DNA at target gene promoters, we next analyzed how CRY1 would affect hypoxia and HIF-dependent gene expression. First, we performed a series of functional reporter gene assays in HepG2 cells. Upon cotransfection of these cells with the hypoxia- and HIF-responsive wild-type (WT) human PAI-1 promoter Luc construct (pGL3-hPAI-806/+19) and an expression vector for CRY1 we found that the hypoxia-mediated increase in Luc activity was reduced in the presence of CRY1. This effect was mediated via the hypoxia responsive element (HRE) within the PAI-1 promoter because a construct with a mutated element (pGL3-hPAI-HREm) did not display this effect on Luc activity ([Figure 7](#fig7){ref-type="fig"}A). Vice versa, when we employed MEFs deficient for either CRY1 (ΔCRY1) or CRY2 (ΔCRY2) to measure PAI-1 expression, we found that deficiency of CRY1, but not CRY2, enhanced PAI-1 levels already under normoxia to almost the same levels as under hypoxia ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3C). Reintroduction of CRY1 ([Figures S3](#mmc1){ref-type="supplementary-material"}D and S3E) rescued the hypoxia-dependent PAI-1 expression indicating that these effects are largely CRY1 specific. In line with the interaction assays, these rescue effects were dependent on the tail region of CRY1 since only full-length CRY1, but not CRY1-Δtail, rescued the hypoxia-dependent induction of PAI-1 ([Figures S3](#mmc1){ref-type="supplementary-material"}D and S3E). Thus, CRY1 appears to function as inhibitor of the hypoxia-dependent PAI-1 gene expression.Figure 7CRY1 Inhibits Binding of HIF-1α to Its Target Gene Promoters(A and B) Cells were cotransfected with an expression vector for CRY1 along with either (A) the wild-type human PAI-1 promoter Luc construct (pGL3-hPAI-806/+19) or a PAI-1 promoter with a mutated hypoxia-responsive element (HRE) (pGL3-hPAI-HREm) as well as with (B) Luc reporter gene constructs containing three HIF-binding HREs (pGL3-HRE) or three mutated HREs (pGL3-HREm) in front of the SV40 promoter and cultured under normoxia (16% O~2~) and hypoxia (5% O~2~) for 24 h. The Luc activity of pGL3-hPAI-806/+19-, pGL3-hPAI-HREm-, pGL3-HRE-, or pGL3-HREm-transfected cells at 16% O~2~ was set to 1. Values are means ± SEM of at least three independent culture experiments, each performed in duplicate. Statistics, Student\'s t test for paired values: \*significant difference, p ≤ 0.05.(C) Cells were cotransfected with pGL3-HRE or pGL3-HREm Luc reporter gene constructs and expression vectors encoding CRY1, HIF-1α, and ARNT alone or in combination. In each experiment the Luc activity of pGL3-HRE- or pGL3-HREm-transfected cells at 16% O~2~ was set to 1. Values are means ± SEM of at least three independent culture experiments, each performed in duplicate. Statistics, Student\'s t test for paired values: ^∗^significant difference, p ≤ 0.05.(D) Chromatin immunoprecipitation (ChIP) was performed on cell lysates from formaldehyde cross-linked wild-type or CRY1-deficient MEFs, cultured under normoxia or hypoxia overnight. DNA fragments were co-precipitated with antibodies against mouse HIF-1α and amplified by quantitative PCR using primers specific for the mouse PAI-1, VEGF-A, PGK-1, and GLUT-1 promoters containing the corresponding HRE. Chromatin immunoprecipitation without antibody or using IgG instead of antibody served as additional specificity controls. Differences in the HIF-1α DNA-binding efficiency in wild-type and ΔCRY1 MEFs were calculated by the fold enrichment method relative to the IgG control. Values are means ± SEM of three independent experiments. Statistics, Student\'s t test for paired values: \*significant difference, p ≤ 0.05.

Next, we aimed to substantiate the inhibitory effect of CRY1 for HIF-driven genes and HIFs. To do this, we used bona fide hypoxia reporters containing either three WT HIF-binding HREs or three mutated HREs in front of the SV40 promoter and the luciferase gene. We then cotransfected these reporters together with a CRY1 expression vector or empty control vector into HepG2 cells. Hypoxia induced Luc activity in the control cells, whereas expression of CRY1 predominantly abolished Luc activity under hypoxia ([Figure 7](#fig7){ref-type="fig"}B). This effect was specific because mutation of critical nucleotides in the HRE (pGL3-HREm) abolished the induction of Luc activity under hypoxia and the repressive effect of CRY1 ([Figure 7](#fig7){ref-type="fig"}B).

As HIFs are dimers consisting of HIF-α and HIF-β (ARNT) subunits, we next investigated whether the CRY1 effect is primarily dependent on each subunit by using the pGL3-HRE Luc construct and the pGL3-HREm construct together with a CRY1 expression vector and HIF-1α, ARNT, or an empty control vector. We found that overexpression of CRY1 together with HIF-1α ([Figure 7](#fig7){ref-type="fig"}C) or HIF-2α ([Figure S4](#mmc1){ref-type="supplementary-material"}), but not with ARNT, compromised the ability of HIF-1α to induce HRE-driven Luc activity. Furthermore, cotransfection of the Luc construct with mutant HREs (pGL3-HREm) along with the respective expression vectors alone or in combination resulted in Luc activities comparable with the control ([Figure 7](#fig7){ref-type="fig"}C). These results, together with the interaction data, suggest that CRY1 represses HIF-1α function.

To understand whether the inhibitory effect of CRY1 is accompanied by a reduced binding of HIF-1α to target gene promoters *in vivo*, we performed chromatin immunoprecipitation (ChIP) assays with WT MEFs or CRY1-deficient MEFs cultured under normoxia or hypoxia. The ChIP assays were performed with either unspecific IgG or specific antibodies against mouse HIF-1α or HIF-2α and PCR primers, which allowed amplification of the HIF-binding PAI-1, VEGF-A, PGK-1, and GLUT-1 promoters ([@bib23], [@bib65], [@bib70], [@bib58]). The assays from WT MEFs reveal that both HIF-1α and HIF-2α preferentially associate with those promoter regions under hypoxia, whereas CRY1-deficient cells bound HIFs already under normoxia ([Figures 7](#fig7){ref-type="fig"}D and [S5](#mmc1){ref-type="supplementary-material"}). Thereby, the normoxic binding of HIF-1α to each studied promoter in ΔCRY1 cells was already about 2- to 6-fold higher when compared with WT MEFs ([Figure 7](#fig7){ref-type="fig"}D). This binding was further increased in ΔCRY1 cells under hypoxia ([Figures 7](#fig7){ref-type="fig"}D and [S5](#mmc1){ref-type="supplementary-material"}). Together, these results indicate that the presence of CRY1 is able to reduce the binding of HIFs to the PAI-1, VEGF-A, PGK-1, and GLUT1 promoters.

Absence of CRY1 Increases HIF-1α Half-Life and Induces Its Transcription {#sec2.8}
------------------------------------------------------------------------

Owing to the fact that CRY1 reduces binding of HIF-1α to its target gene promoters and that it is mainly regulated by post-translational stabilization, we hypothesized that CRY1 may promote HIF-1α degradation. To analyze this, we measured the HIF-1α protein half-life in the absence and presence of CRY1. Interestingly, we found that ΔCRY1 cells had higher HIF-1α protein levels than WT MEFs ([Figure 8](#fig8){ref-type="fig"}A). In addition, the CRY1-deficient cells displayed a prolonged HIF-1α half-life (t~1/2~: 57 min versus ∼45 min in WT cells) ([Figures 8](#fig8){ref-type="fig"}A and 8B). Furthermore, we examined whether lack of CRY1 would also affect HIF-1α mRNA levels. Concomitant with the increase in HIF-1α protein levels, we also found that the HIF-1α mRNA levels were increased by about 2-fold in the CRY1-deficient cells ([Figure 8](#fig8){ref-type="fig"}C). In addition, we found that the HIF-2α mRNA levels were induced by about 10-fold ([Figure 8](#fig8){ref-type="fig"}C). Overall, these data indicate that the CRY1-mediated functional repression of HIF-1α DNA binding is also accompanied by reduced transcription and enhanced HIF-1α protein degradation.Figure 8CRY1 Deficiency Increases HIF-1α Protein Half-Life and Transcription(A and B) Measurement of HIF-1α protein half-life in wild-type (WT) and CRY-deficient MEFs (ΔCRY1). Cells were cultured for 4 h under hypoxia (5% O~2~) and after inhibition of protein synthesis with cycloheximide (CHX; 10 μg/mL), endogenous HIF-1α protein levels were determined by western blot analysis with an antibody against mouse HIF-1α. Autoradiographic signals were obtained by chemiluminescence and quantified. Values are means ± SEM of three independent experiments. (A) Representative western blots. (B) Quantification of HIF-1α half-life.(C) Quantitative qRT-PCR data. The values in wild-type MEFs (WT) were set to 1. Values represent means ± SEM of at least three independent experiments. Statistics, Student\'s t test for paired values: \*significant difference WT versus CRY1-deficient cells; p ≤ 0.05.

CRY1 and HIFs Have Opposite Roles in Cell Proliferation and Migration {#sec2.9}
---------------------------------------------------------------------

The aforementioned findings suggest a reciprocal regulation of CRY1 and HIF-1α that would be of importance for cellular growth and survival, in particular during tumor development. To get an overview, we checked CRY1 and HIF-1α mRNA levels in cancer tissues and the corresponding normal tissues from the Oncomine ([www.oncomine.org](http://www.oncomine.org){#intref0010}) database by applying a threshold of a \>10-fold change and p value of 0.05. The results show that HIF-1α and CRY1 could be oppositely regulated in different tumor entities. In none of the cases HIF1α and CRY1 were regulated in the same manner, i.e., they were never together up- or downregulated in the same dataset. The reason(s) why HIF-1α expression was upregulated and CRY1 expression was not downregulated in the first and sixth microarray datasets and why HIF-1α expression was not upregulated and CRY1 was downregulated in the second and fifth microarray datasets are not known but may reflect the different status of tumor driving mutations, which certainly confound the regulation ([Figure 9](#fig9){ref-type="fig"}). Similarly, we observed CRY1 mRNA induction in HIF-1α-deficient cells ([Figure S7](#mmc1){ref-type="supplementary-material"}). Given that HIF-1α overexpression is associated with poor survival in several patients with cancer ([@bib60]), these data together with the higher HIF-1α levels in ΔCRY1 cells imply that loss of CRY1 can promote cell growth. Indeed, we found that CRY1-deficient cells showed a higher rate in proliferation, migration, and colony formation than their WT counterparts ([Figures 10](#fig10){ref-type="fig"}B--10F and [S6](#mmc1){ref-type="supplementary-material"}). To assess whether these functional differences are, at least in part, mediated by HIFs we re-investigated cellular proliferation, motility, and the ability to form colonies in CRY1-deficient cells with either CRISPR/Cas9-mediated HIF-1α deletion ([Figure 10](#fig10){ref-type="fig"}A) or short hairpin RNA (shRNA)-mediated knockdown of HIF-1α or HIF-2α ([Figure S6](#mmc1){ref-type="supplementary-material"}). In contrast to CRY1 deficiency, lack of HIF-1α reduced proliferation ([Figures 10](#fig10){ref-type="fig"}B and 10C), motility ([Figures 10](#fig10){ref-type="fig"}E and 10F) and colony formation ([Figure 10](#fig10){ref-type="fig"}D). Interestingly, the ΔHIF-1α-ΔCRY1 cells harboring the combined knockout of HIF-1α and CRY1 displayed growth, motility, and colony-forming properties resembling those of WT cells ([Figures 10](#fig10){ref-type="fig"}B--10E). Similarly, we introduced scrambled non-effective shRNA or HIF-1α shRNA via retroviral infection into WT and ΔCRY1 cells. Again, knockdown of HIF-1α or HIF-2α reduced the positive effects on migration and soft agar colony formation exerted by CRY1 deficiency alone ([Figures S6](#mmc1){ref-type="supplementary-material"}A--S6C).Figure 9CRY-1 and HIF-1α Show an Opposite Expression Pattern in Human Cancer CohortsAnalysis of CRY1 and HIF1A mRNA expression profiles in the Oncomine database. Six microarray datasets from different cancer entities were analyzed for CRY1 and HIF1A mRNA expression and compared with normal tissue using a threshold of \>10-fold change and a p value \<0.05. Red, upregulated in cancer versus normal tissue; blue, downregulated in cancer versus normal tissue. Data are presented as log2 median-centered intensity with the median rank of CRY1 and HIF1A mRNA through each dataset analysis. The rank for a gene is the median rank for that gene across each of the analyses. The p value for a gene is its p value for the median-ranked analysis.Figure 10CRY-1 and HIF-1α Show an Opposite Role on Cell Proliferation and Migration(A) Representative HIF-1α western blots in WT MEFs, ΔCRY1, ΔHIF-1α, and ΔCRY1/ΔHIF-1α MEFs.(B) Proliferation rate of WT, ΔCRY1, ΔHIF-1α, and ΔCRY1/ΔHIF-1α cells quantified by dynamic imaging using percentage of confluence at 3-h time intervals.(C) Chart of 24- and 36-h time points. Statistics, Student\'s t test for paired values: \*significant difference, p ≤ 0.01.(D) Quantification of the colony formation ability of WT, ΔCRY1, ΔHIF-1α, and ΔCRY1/ΔHIF-1α cells as measured by soft agar assay. The cells were plated in soft agar and allowed to grow for 2 weeks under hypoxia. Cell growth was measured using Resazurin staining in a microplate reader with an excitation wavelength of 584 nm and emission at 612 nm. The OD~612~ in WT MEFs was set to 100%. Statistics, Student\'s t test for paired values: \*significant difference, p \< 0.05.(E) Representative images of the wound recovery of WT, ΔCRY1, ΔHIF-1α, and ΔCRY1/ΔHIF-1α cells at 0, 12, and 24 h after introduction of the wound. Scale bar, 300 μm.(F) Chart of 12- and 24-h time points. Statistics, Student\'s t test for paired values: \*significant difference, p \< 0.01.

Thus concomitant deletion of HIFs in ΔCRY1 cells significantly reduced the stimulating effects exerted by the absence of CRY1 on cellular growth, colony formation, and cell migration. Together, these data indicate that CRY1 and HIFs have an opposite role on cellular growth.

Discussion {#sec3}
==========

The current study extends recently reported findings on the interplay between the circadian clock and the hypoxia pathway ([@bib1], [@bib71], [@bib53]) by providing detailed mechanistic insights indicating how the circadian clock component CRY1 can regulate the hypoxia response pathway at the level of HIF-1α and HIF-2α. In particular we show that (1) CRY1 directly interacts with both HIF-1α and HIF-2α, (2) that the interaction of CRY1 with HIFs masks the DNA-binding domain of HIFs and consequently changes HIF DNA binding and expression of HIF target genes, and (3) that the CRY1-HIFα interaction is important for cellular growth.

By broadening the knowledge about CRY1\'s involvement in more than the circadian clock pathway, the current study also extends the existing information about the interplay between the circadian clock and the hypoxia response pathway. Although this cross talk was proposed on the basis of *in vitro* findings almost 20 years ago ([@bib22]), a functional validation presenting a reciprocal regulation between the positive clock limb protein BMAL1 and HIF-1α ([@bib53]) was just recently reported while this study on the negative limb was ongoing.

Our data show that hypoxia can modulate the circadian rhythm *in vivo* and *in vitro*. This is in line with findings of a recent study demonstrating that mimicry of circadian physiological oxygen rhythms as occurring in mouse blood can affect the setting of the clock ([@bib1]). In addition, we show that mice under chronic hypoxia become arrhythmic in total darkness (DD) indicating more severe effects of hypoxia on the clock in general ([Figure 1](#fig1){ref-type="fig"}). Although the reasons are not known yet, these activity data may be the result of a partial uncoupling of central and peripheral clocks due to disturbed adaptation to chronic hypoxia similar to that seen with restricted feeding ([@bib11]). This may express as arrhythmicity in periods coinciding with an increased oxygen consumption ([@bib1]) such as the onset of activity and food ingestion, which in mice normally occur during the dark phase of the daily rhythm.

A complimentary approach with Per2:Luc cells exposed to hypoxia as well as with mBmal1:Luc circadian reporter cells in which we overexpressed variants of HIF-1α and HIF-2α revealed that hypoxia and HIFs can not only shorten the period but also decrease the amplitude of the clock ([Figures 2](#fig2){ref-type="fig"} and [S1](#mmc1){ref-type="supplementary-material"}). The amplitude effects of the HIFs seen here are in line with previous studies in which C2C12 and U2OS cells were treated with DMOG ([@bib71], [@bib53]). Interestingly, our data appeared to be in contrast to one study ([@bib71]) wherein overexpression of a degradation-resistant HIF1α (HIF1α-P402A/P564A) resulted in a lengthening of the period of up to 4 h in U2OS cells. The reasons for the discrepancies might be multiple and could be attributable to the different model systems used (U2OS osteosarcoma cells there versus non-cancer mammalian fibroblasts in our study) or the different way of cell synchronization (dexamethasone versus forskolin in our study). In addition, the other study used the doxycycline-dependent tetR system to overexpress HIF-1α in U2OS cells. Hence, secondary effects of the doxycycline treatment, which are known to inhibit protein translation in mitochondria and to impair metabolism may lead to effects that can confound experimental results ([@bib48], [@bib5]). Nonetheless, and despite the differences, both studies underline the important roles of HIF-1α as circadian modulator.

Although no study, including the present, can yet explain the detailed mechanism by which HIFs and DMOG affect the period, it is tempting to speculate that this may be mediated by the proposed effects of HIF on BMAL1 ([@bib53]). Indeed, deletion of HIF-1α resulted in a dramatic reduction in BMAL1 mRNA levels ([Figure S7](#mmc1){ref-type="supplementary-material"}) in line with another study wherein overexpression of HIF-1α induced it ([@bib77]). However, HIFs and DMOG appear to act by a different mechanism when seeing the effects on the period. In the present and previous studies ([@bib71], [@bib53]) DMOG lengthened the period ([Figure S1](#mmc1){ref-type="supplementary-material"}), whereas overexpression of HIFs shortened it ([Figures 2](#fig2){ref-type="fig"} and [S1](#mmc1){ref-type="supplementary-material"}). The difference in period length between DMOG and HIFs is explainable by the rather pleiotropic effects of DMOG, which is a synthetic analog of α-ketoglutarate/2-oxoglutarate. As such, DMOG can act as a pan-inhibitor of α-ketoglutarate/2-oxoglutarate-dependent dioxygenases, a family consisting of about ∼70 enzymes in humans, among them the HIF-prolyl 4-hydroxylases ([@bib21], [@bib33]). Consequently, a number of HIF-independent effects may influence the data achieved upon usage of DMOG. In line are the results obtained upon knockdown of the α-ketoglutarate/2-oxoglutarate-dependent dioxygenases FIH-1 and the EglN family, which also resulted in a lengthened period ([@bib71]). To circumvent the pleiotropic DMOG effects, we used a hydroxylation-resistant HIF-1α variant (PPN) to specify whether it can mimic the shorter period as seen during chronic hypoxia. Importantly, both HIF-1α and HIF-2α could resemble the effects of hypoxia on the period ([Figures 2](#fig2){ref-type="fig"} and [S1](#mmc1){ref-type="supplementary-material"}). Thus the difference in period length upon DMOG usage or EglN and FIH-1 knockdown versus hypoxia or HIF overexpression as seen in this study can be attributed to non-HIF targets of which several, so far unknown, may be involved in clock regulation ([@bib25]). Together, all these data suggest that the hypoxia-signaling pathway may have different layers that can affect the circadian period and amplitude.

Intrigued by the HIF effects on the circadian period, and given that CRY proteins represent dominant critical regulators of the circadian period length in humans and mice ([@bib67], [@bib68], [@bib40], [@bib20], [@bib49], [@bib51], [@bib62], [@bib52]) we hypothesized a connection between HIFs and CRYs. Therefore, we probed whether CRY1 and CRY2 can interact with HIF-1α and HIF-2α, and indeed our experiments revealed that both CRY proteins were able to undergo interaction with the two HIF proteins ([Figures 4](#fig4){ref-type="fig"} and [S2](#mmc1){ref-type="supplementary-material"}).

The CRY1 protein contains a conserved photolyase homology region crucially involved in repression of CLOCK/BMAL1; a C-terminal helix also known as the predicted coiled coil (CC), which interacts with PER2 and FBXL3 in a mutually exclusive manner; and a C-terminal extension also referred to as the "tail" ([Figure 5](#fig5){ref-type="fig"}) ([@bib6], [@bib46]). Our mapping experiments showed that HIF-1α interacts with the CRY1 "tail" region, a part of the protein ([Figure 5](#fig5){ref-type="fig"}), which has the ability to modulate the period length and amplitude of the resulting oscillation ([@bib32], [@bib72]). In line, a recent report showed that a dominant CRY1 allele coding for a protein with a deletion of 24 residues in the tail region ([@bib52]) caused lengthening of the circadian period and could be linked to familial delayed sleep phase disorder. Thus the effects seen under hypoxia on the period length are in accord with the interaction of HIF-1α with CRY1\'s tail region. Furthermore, the tail has been shown to affect CRY1 translocation, to interact with the BMAL1 transactivation domain possibly in an acetylation-dependent fashion, and to be phosphorylated in a manner that involves regulation by DNA-PK ([@bib72], [@bib7], [@bib10], [@bib19]). In addition, the existence of a nuclear localization signal in the CRY1 tail coincides well with the nuclear localization of its interaction with HIFs as seen in the BiFC assays ([Figures 4](#fig4){ref-type="fig"} and [S2](#mmc1){ref-type="supplementary-material"}). In line, the bHLH domain of HIF-1α, which appears to work as the CRY1 interaction module ([Figure 6](#fig6){ref-type="fig"}), also contains a nuclear localization sequence ([@bib28]). Although not directly tested in this study, a similar mode of interaction is likely occurring with HIF-2α because both share an amino acid sequence identity of ∼85% in the bHLH domain.

As the HIF bHLH domain is primarily involved in DNA binding, it is conceivable that the CRY1 tail could affect binding of HIFs to target gene promoters causing a repression of their expression. Thereby the repressive effect of CRY1 may not only depend solely on HIF-1α but also on the promoter context. This is exemplified with the PAI-1 promoter where CRY1 did not repress its activity under normoxia, whereas it clearly suppressed its hypoxia-dependent induction. To minimize the influence of the promoter context and to generalize the findings with respect to HIFs, we then used a bona fide hypoxia reporter containing three HREs as enhancers in front of the SV40 promoter and the luciferase gene. Indeed, these HRE reporter gene assays revealed that CRY1 suppressed their activity under normoxia and their hypoxia and HIF-1-dependent induction. Vice versa, the ChIP experiments from CRY1-deficient cells showed enhanced binding of HIFs to target gene promoters under both normoxia and hypoxia ([Figures 7](#fig7){ref-type="fig"}D and [S5](#mmc1){ref-type="supplementary-material"}). Together, these effects need to be seen in context with our data showing that absence of CRY1 regulates HIF-1α at two levels, namely, by increasing its transcription and its stability ([Figure 8](#fig8){ref-type="fig"}). Consequently, the net effect is an increase in HIF-1α binding to its enhancers under both conditions. Overall, these data point to a suppressive role of CRY1, and in particular its tail, in the transcriptional response toward hypoxia at various stages of the circadian cycle.

The current data are also in agreement with another recent study also showing enhanced HIF-1α levels in CRY-deficient cells, whereas BMAL1 absence decreased HIF-1α levels ([@bib53]). Similarly, Per2 supported recruitment of HIF-1α to the VEGF promoter ([@bib36]). Together with reports from mouse liver and cardiac tissue, showing that *Hif1*α mRNA levels cycled in a circadian manner ([@bib13], [@bib71]) and data showing a rhythmic appearance of nuclear HIF1α in mouse brain and kidney ([@bib1]), the current findings substantiate the existence of a feedback mechanism in which the circadian clock pathway can regulate HIF-1α expression.

Earlier findings from different cancer entities such as chronic myeloid leukemia ([@bib74]), B cell chronic lymphocytic leukemia ([@bib26]), prostate cancer ([@bib79]), epithelial ovarian cancer ([@bib66]), and colon cancer ([@bib45], [@bib24]) indicate a reduced CRY1 expression and associated this, as well as a deregulation in *Bmal1* or *Per2* expression ([@bib24]), to be a negative prognostic marker.

Vice versa, HIFs are frequently found to be enriched in the hypoxic areas of solid tumors ([@bib64], [@bib78]). By showing that CRY1 deficiency induces HIF levels ([Figures 10](#fig10){ref-type="fig"} and [S6](#mmc1){ref-type="supplementary-material"}) and accelerates proliferation and migration, two key aspects relevant to carcinogenesis, and that knocking out HIFs either by CRISPR/Cas9 or by the use of shRNAs reversed these effects, our study now provides a mechanistic link between the above-mentioned genetic association studies.

Although these findings underline the connection between CRY1 and HIFs, it appears that other regulators involved in carcinogenesis can also be regulated by CRY1. For example, several findings from both *Per* and *Cry* knockout mice strongly suggest that their dysfunction cooperates with loss of *p53* during carcinogenesis ([@bib16]). This is also in agreement with studies showing the complex interconnections between the individual components of the circadian clock with nucleotide excision repair and DNA damage in mice ([@bib30], [@bib29]) which affect not only carcinogenesis but also aging.

In summary, the current study presents a mechanistic link by which the lack of circadian control at the CRY1 level can favor the action of HIFs during cellular growth, which underpins that chronic misalignment between our lifestyle and the rhythm dictated by our endogenous circadian clock is associated with an increased risk for various diseases including cancer.

Limitations of the Study {#sec3.1}
------------------------

In this study we made use of mice and MEFs to investigate the cross talk between HIFs and CRY1. Although this study provided novel insights into how CRY1 affects the HIF system in MEFs, subsequent studies are necessary to investigate the implication for cancer cells and cancer treatment. It is likely, however, that other circadian proteins (such as tCK2) could contribute to the regulation as well. As different regulators may affect CRY1 expression and activity in different ways, their exact roles and contributions need to be further studied.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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Document S1. Transparent Methods, Figures S1--S7, and Tables S1 and S2
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